news
Testosterone Therapy Protects Bone Density in Postmenopausal Women
Clinical research indicates low-dose testosterone preserves bone mineral density in postmenopausal women, challenging estrogen-only hormone replacement models. Women produce substantial testosterone throughout life, yet existing prescribing guidelines almost exclusively restrict treatment to sexual dysfunction. The findings offer a concrete hormonal mechanism for treating accelerated midlife bone loss.
Clinical research indicates low-dose testosterone preserves bone mineral density in postmenopausal women, challenging estrogen-only hormone replacement models. Women produce substantial testosterone throughout life, yet existing prescribing guidelines almost exclusively restrict treatment to sexual dysfunction. The findings offer a concrete hormonal mechanism for treating accelerated midlife bone loss.
The architecture take
I spent years assuming testosterone was just an afterthought for women, mostly reserved for off-label libido patches when nothing else worked. That was my mistake. Women naturally churn out more testosterone than estrogen across a normal lifespan, and our osteoblasts have androgen receptors waiting for a signal. When ovarian output plummets during menopause, bone resorption speeds up while formation stalls. Estrogen replacement slows the breakdown, but testosterone stimulates osteoblasts to lay down new bone density. I spoke with an endocrinologist last month who told me she still can't get insurance to cover androgen scripts for women without a sexual dysfunction diagnosis. It's absurd. If future trials confirm these dual-action protocols without nasty lipid shifts, the standard perimenopause toolkit won't stay limited to estradiol and progesterone for long. Watch how specialist longevity clinics run with this first.